Guidelines on use of vena cava filters.

GUIDELINE TITLE
Guidelines on use of vena cava filters.

BIBLIOGRAPHIC SOURCE(S)
British Committee for Standards in Haematology Writing Group, Baglin TP, Brush J, Streiff M. Guidelines on use of vena cava filters. Br J Haematol 2006 Sep;134(6):590-5. [22 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

December 3, 2008, Innohep (tinzaparin): The U.S. Food and Drug Administration (FDA) has requested that the labeling for Innohep be revised to better describe overall study results which suggest that, when compared to unfractionated heparin, Innohep increases the risk of death for elderly patients (i.e., 70 years of age and older) with renal insufficiency. Healthcare professionals should consider the use of alternative treatments to Innohep when treating elderly patients over 70 years of age with renal insufficiency and deep vein thrombosis (DVT), pulmonary embolism (PE), or both.

abrir aquí para acceder al documento AHRQ NGC completo:
Guidelines on use of vena cava filters.